Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Alerts
Advertising
Job board
Subscribe
Contact
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
New Therapeutic Targets in Cardiovascular Diseases (Upcoming)
Immunometabolism (Upcoming)
Circadian Rhythm (Oct 2021)
Gut-Brain Axis (Jul 2021)
Tumor Microenvironment (Mar 2021)
100th Anniversary of Insulin's Discovery (Jan 2021)
Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Concise Communication
Editorials
Viewpoint
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?
George Kunos, … , Tony Jourdan, Joseph Tam
George Kunos, … , Tony Jourdan, Joseph Tam
Published January 4, 2022
Citation Information:
J Clin Invest.
2022;
132(1)
:e155330.
https://doi.org/10.1172/JCI155330
.
View:
Text
|
PDF
Letter to the Editor
Metabolism
Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?
Text
PDF
Abstract
Authors
George Kunos, Tony Jourdan, Joseph Tam
×
Full Text PDF |
Download
(69.70 KB)
